Ines Bojanic1, Sanja Mazic1, Ljubica Rajic2, Gordana Jakovljevic3, Jasminka Stepan3, Branka Golubic Cepulic1. 1. Department of Transfusion Medicine and Transplantation Biology, University Hospital Centre, Zagreb, Croatia. 2. Department of Paediatrics, University Hospital Centre, Zagreb, Croatia. 3. Department of Oncology, Children's Hospital Zagreb, Zagreb, Croatia.
Abstract
BACKGROUND: The collection of peripheral blood stem cells, although now a routine procedure, is still a challenge in low body weight children because of specific technical and clinical issues. For paediatric patients it is crucial to obtain an adequate number of CD34+ cells with the minimum number of procedures: this can be done using large volume leukapheresis (LVL). MATERIALS AND METHODS: We analysed the efficacy and safety of 54 autologous LVL performed in 50 children (33 [66%] males and 17 [34%] females), median age 2 years (range, 1-5) and median body weight 12 kg (range, 6-15). The procedures were performed with a COBE Spectra previously primed with red blood cells; ACD-A solution and heparin were used as anticoagulants. RESULTS: The target CD34+ cell dose (≥5×10/kg body weight) were collected with one LVL in 46 (92%) patients, while four (8%) patients needed another procedure. All our LVL were well tolerated. Side effects were observed in five (9.2%) patients and one procedure had to be discontinued because of catheter-related haemorrhage. The platelet count decreased significantly (p<0.001) after each procedure but without bleeding or need for transfusion support. DISCUSSION: Our experience confirms that LVL is efficient and safe even in small children, if the procedure is adjusted considering the weight and age of child. The most important factors are good venous access, adequate preparation of the child's electrolyte status, and surroundings in which the small child as well as parents feel comfortable, and can tolerate the procedure better. Although a median platelet loss of 50% can be expected, LVL is safe and reduces the overall number of procedures required. It can be recommended for peripheral blood stem cell collection even in small body weight children with malignant diseases, particularly those who mobilise low numbers of CD34+ cells.
BACKGROUND: The collection of peripheral blood stem cells, although now a routine procedure, is still a challenge in low body weight children because of specific technical and clinical issues. For paediatric patients it is crucial to obtain an adequate number of CD34+ cells with the minimum number of procedures: this can be done using large volume leukapheresis (LVL). MATERIALS AND METHODS: We analysed the efficacy and safety of 54 autologous LVL performed in 50 children (33 [66%] males and 17 [34%] females), median age 2 years (range, 1-5) and median body weight 12 kg (range, 6-15). The procedures were performed with a COBE Spectra previously primed with red blood cells; ACD-A solution and heparin were used as anticoagulants. RESULTS: The target CD34+ cell dose (≥5×10/kg body weight) were collected with one LVL in 46 (92%) patients, while four (8%) patients needed another procedure. All our LVL were well tolerated. Side effects were observed in five (9.2%) patients and one procedure had to be discontinued because of catheter-related haemorrhage. The platelet count decreased significantly (p<0.001) after each procedure but without bleeding or need for transfusion support. DISCUSSION: Our experience confirms that LVL is efficient and safe even in small children, if the procedure is adjusted considering the weight and age of child. The most important factors are good venous access, adequate preparation of the child's electrolyte status, and surroundings in which the small child as well as parents feel comfortable, and can tolerate the procedure better. Although a median platelet loss of 50% can be expected, LVL is safe and reduces the overall number of procedures required. It can be recommended for peripheral blood stem cell collection even in small body weight children with malignant diseases, particularly those who mobilise low numbers of CD34+ cells.
Authors: J Kanold; M Berger; P Halle; C Rapatel; C Schoepfer; L de Lumley; J P Vannier; P Lutz; D Plantaz; J L Stéphan; G Malpuech; F Deméocq Journal: Bone Marrow Transplant Date: 1998-01 Impact factor: 5.483
Authors: A T Anguita-Compagnon; M T Dibarrart; J Palma; L Paredes; C Mosso; R Montalva; L Salas; D Araos; I Delgado; A Majlis Journal: Transplant Proc Date: 2010 Jan-Feb Impact factor: 1.066
Authors: J Kanold; P Halle; M Berger; C Rapatel; J B Palcoux; C Rouzier; L deLumley; J P Vannier; J L Stéphan; F Deméocq Journal: Med Pediatr Oncol Date: 1999-01
Authors: J Delgado; M C Fernandez-Jimenez; A Martinez; A Sastre; P Garcia-Miguel; F Hernandez-Navarro; R Arrieta Journal: Cytotherapy Date: 2004 Impact factor: 5.414
Authors: Helen L Wu; Justin M Greene; Tonya Swanson; Christine Shriver-Munsch; Kimberly Armantrout; Whitney C Weber; Katherine B Bateman; Nicholas M Maier; Mina Northrup; Alfred W Legasse; Cassandra Moats; Michael K Axthelm; Jeremy Smedley; Richard T Maziarz; Lauren Drew Martin; Theodore Hobbs; Benjamin J Burwitz; Jonah B Sacha Journal: J Clin Apher Date: 2020-09-17 Impact factor: 2.821